Anton Y. Peleg Honoured By American Society For Microbiology
Main Category: MRSA / Drug ResistanceAlso Included In: Infectious Diseases / Bacteria / Viruses; Biology / Biochemistry; Genetics
Article Date: 20 Aug 2009 - 5:00 PDT
| Patient / Public: | ![]() |
5 (1 votes) |
| Healthcare Prof: | ![]() |
5 (1 votes) |
The 2009 American Society for Microbiology (ASM) ICAAC Young Investigator Award will be presented to Anton Y. Peleg, Research Fellow, Division of Infectious Diseases, Massachusetts General Hospital, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA. Sponsored by the ASM, this award recognizes early career scientists for research excellence in microbiology and infectious diseases.
Dr. Peleg is recognized as an expert on the clinical impact, epidemiology, and management of infections due to multidrug-resistant Gram-negative bacteria, specifically Acinetobacter. He provided the first description of carbapenemase genes in Australia and designed phenotypic methods for their detection in Gram-negative organisms. He also provided the first reports of tigecycline resistance in Acinetobacter and identified the mechanism of resistance as over-expression of a multi-drug efflux pump.
Dr. Peleg's more recent research has been on prokaryote-eukaryote interactions identified using the Caenorhabditis elegans model. His work has shown the antagonistic interaction between Acinetobacter and Candida, pathogens that frequently coinhabit patients. Furthermore, Dr. Peleg also showed that Acinetobacter was capable of inhibiting C. albicans biofilm formation, another important virulence mechanism of this fungus. He developed a co-infection screen assay in C. elegans and an A. baumannii mutant library to assess within this assay the identification of the molecular mechanisms responsible for the interaction. These tools helped Dr. Peleg identify a gene, known as the gacS-like sensor kinase gene, in A. baumannii.
Dr. Peleg completed his medical degree at Monash University Medical School and his medical residency at the Alfred Hospital, Melbourne, Australia . He completed his Infectious Diseases advanced training in Australia before moving to the U. S. where he completed a clinical research fellowship at the University of Pittsburgh Medical Center.
Source:
Garth Hogan
American Society for Microbiology
Visit our mrsa / drug resistance section for the latest news on this subject.
MLA
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/161309.php>
APA
http://www.medicalnewstoday.com/releases/161309.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



